Key Insights

Highlights

Success Rate

82% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

7.4%

2 terminated out of 27 trials

Success Rate

81.8%

-4.7% vs benchmark

Late-Stage Pipeline

11%

3 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed with results

Key Signals

1 with results82% success

Data Visualizations

Phase Distribution

20Total
Not Applicable (17)
P 3 (1)
P 4 (2)

Trial Status

Unknown11
Completed9
Terminated2
Recruiting2
Enrolling By Invitation1
Withdrawn1

Trial Success Rate

81.8%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT04080492RecruitingPrimary

A Cardiac Disease Quality of Life Study

NCT05257772Not ApplicableActive Not Recruiting

Electromechanically Optimised Right Ventricular Pacing In Hypertrophic Cardiomyopathy (EMORI-HCM)

NCT04770142Not ApplicableTerminatedPrimary

First-in-Man Early Feasibility Study for Transcatheter HOCM Septal Ablation

NCT04141891Not ApplicableCompleted

Advancing Understanding of Transportation Options

NCT05332691Not ApplicableRecruitingPrimary

Transapical Beating-heart Septal Myectomy in Patient With Hypertrophic Obstructive Cardiomyopathy

NCT06167876Not ApplicableUnknownPrimary

Safety and Efficacy of Stereotactic Body Radiotherapy in the Treatment of Hypertrophic Obstructive Cardiomyopathy

NCT04066777Not ApplicableCompletedPrimary

The Effect of TASH in Patients With HOCM

NCT05100420Enrolling By Invitation

Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository

NCT06003478UnknownPrimary

The Safety and Influencing Factors of Liwen Procedure in The Treatment of Hypertrophic Cardiomyopathy

NCT05957419Not ApplicableUnknownPrimary

Transapical Beating-Heart Septal Myectomy in Patient With Hypertrophic Obstructive Cardiomyopathy: a Multi-Center Study

NCT05850026CompletedPrimary

Mitral Regurgitation in Hypertrophic Obstructive Cardiomyopathy: Fix it in a Simple, Effective and Durable Way!

NCT05687487CompletedPrimary

Residual or Recurrent Obstruction After Septal Myectomy

NCT02674958Phase 3TerminatedPrimary

Mobilization of Endothelial Progenitor Cells and Aspirin

NCT05671367Completed

Association Between Microvascular Resistance and Outcomes in Patients With Obstructive Hypertrophic Cardiomyopathy

NCT04686487Not ApplicableCompletedPrimary

SterEotactic AbLative Radiotherapy in PatiEnts With HypertrophiC ObstrucTive Cardiomyopathy

NCT05025644Phase 4UnknownPrimary

Quantitative Assessment of Hypertrophic Obstructive Cardiomyopathy With Intraoperative Three-dimensional Transesophageal Echocardiography Under Provocative Dobutamine Stress Test

NCT04905173Not ApplicableWithdrawn

Comparison of Squat-to-Stand Maneuver With Amyl Nitrite, Valsalva, and Exercise Stress Echocardiography in Inducing Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy

NCT05073094Phase 4UnknownPrimary

Esmolol for Myocardial Protection in Hypertrophic Obstructive Cardiomyopathy

NCT04777188Not ApplicableCompletedPrimary

Speckle Tracking Echocardiography Analysis of Left Ventricular Myocardium After Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy

NCT04355260Not ApplicableUnknownPrimary

The Clinical Research of the Safety and Effectiveness Evaluation for Using Echocardiography-guided Liwen RF Radiofrequency Ablation System to Treat Hypertrophic Obstructive Cardiomyopathy

Scroll to load more

Research Network

Activity Timeline